Bydureon (exenatide) is a once weekly treatment for patients with type 2 diabetes. Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several actions of the natural hormone called GLP-1 in the body, lowering blood glucose levels mainly through increasing insulin secretion from the pancreas and reducing glucose production in the liver.

Product Information – European Medicines Agency